Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

Visepegenatide

Stage Phase 1/2Stale

Sponsor PegBio Co

Route injection

Sources

registry, as of 2025-11-19Stale

https://clinicaltrials.gov/study/NCT06350812

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PB-119 Injection in Chinese Obese Subjects. Overall status COMPLETED. Phases PHASE1,PHASE2. Lead sponsor PegBio Co., Ltd.. Enrollment 32. Conditions Obesity. The trial is conducted in a single-center, randomized, double-blind, placebocontrolled, dose-increasing design. To evaluate the safety, tolerability, pharmacokinetics(PK) characteristics, efficacy and immunogenicity of PB-119 injection in Chinese obese subjects.

ClinicalTrials.gov NCT06350812 protocol and results modules

Studies

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PB-119 Injection in Chinese Obese Subjects

Registry NCT06350812

Phase Phase 1/2

Status Completed

Enrollment 32

Start 2024-05-27

Primary completion 2024-11-16

Study completion 2024-12-16

PB-119

Regimen once weekly

Weeks 1

Comparator placebo

Population Obesity

Placebo

Regimen once weekly

Weeks 1

Population Obesity